N-803
Drug timelines are a Plus or Pro feature.
26 regulatory and trial events tracked for N-803, covering 2023-08-08 to 2026-04-27. Get the full timeline:
Most recent: Clinical Trial Update: Randomized, Two-Cohort, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In [Phase 3]